지씨지놈 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 조은해, was filed 30 Jan 2026.
지씨지놈: what insiders have been doing
지씨지놈, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). The last twelve months, up to 10 November 2026, brought 4 filings signed by 2 insiders.
Both sides are active: 1 purchase and 3 sales, from 1 insider and 1 insider respectively. The totals do not cover 4 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 1 senior executive.
Compared with its exchange (2,648 companies, median 7 filings), a count of 4 filings is below the norm. Our records for 지씨지놈 go back to 2025, with 1 purchase and 3 sales on the open market in total.
The last purchase on record was published on 30 January 2026, which is 284 days ago. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleTransparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 900,311 sharesKRXDART:20260203000417
- 10,000 sharesShareKRXDART:20260130000505Canonical exit: 30 Apr 2026 (T+90)
- 989,094 sharesShareKRXDART:20251215000460
- 989,094 sharesKRXDART:20251215000456
4 of 4 declarations
About 지씨지놈
지씨지놈 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in the development of genomic and biopharmaceutical solutions.
